<DOC>
	<DOCNO>NCT02032173</DOCNO>
	<brief_summary>To evaluate new treatment regimen space follow-up initial intensive treatment phase patient reduce visual acuity due diabetic macular edema ( DME ) .</brief_summary>
	<brief_title>Efficacy Safety Lucentis® Use Patients With Diabetic Macular Edema Evaluating Spaced Out Follow-up After Intensive Treatment Phase</brief_title>
	<detailed_description />
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Type I type II diabetes HbA1c≤10 % Visual impairment due diabetic macular edema Stable antidiabetic treatment ( since 3 month ) hygienedietary Inflammation infection one eye Women childbearing potential without efficient contraception , pregnant breastfeed Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Ranibizumab</keyword>
	<keyword>Diabetic Macular Edema</keyword>
</DOC>